Of the 270,000 patients with spinal cord injuries in the U.S., approximately one-third report below-level neuropathic pain that is severe or excruciating.
“Until now, no FDA approved treatment options were available in the U.S. for people with neuropathic pain associated with spinal cord injury, a condition which can be extremely disabling,” said Steven J. Romano, MD, senior vice president and head of the medicines development group of Pfizer’s global primary care business unit. “The approval of Lyrica for this indication is a significant milestone.”
Related Articles on Pain Management:
Patient-Controlled Analgesia System Enters Phase III Trials
New Mexico Considers Mandatory Prescription Drug Database
Study: Preventive Migraine Medications Effective but Underused
